<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053841</url>
  </required_header>
  <id_info>
    <org_study_id>22014</org_study_id>
    <nct_id>NCT05053841</nct_id>
  </id_info>
  <brief_title>Implication of Metformin Plus Aromatase Inhibitor in Obese Postmenopausal Breast Cancer Women</brief_title>
  <official_title>Implication of Combined Adjuvant Metformin and Aromatase Inhibitor in Overweight or Obese Postmenopausal Breast Cancer Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <brief_summary>
    <textblock>
      Metformin is an anti-diabetic oral hypoglycemic agent that considered the gold standard&#xD;
      therapy for the treatment of type 2 diabetes. Retrospective analyses show that metformin can&#xD;
      offer therapeutic benefits to patients with several forms of cancer. It also has positive&#xD;
      weight reducing effect on non-diabetic patient by improving insulin sensitivity (although the&#xD;
      exact underlying pathomechanisms remain to be elucidated).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective controlled study aimed to evaluate the effect of combined metformin adjuvant&#xD;
      therapy and aromatase inhibitors (letrozole) in postmenopausal obese breast cancer women. In&#xD;
      addition, to evaluate the effect of weight reduction on aromatase inhibitor efficacy.&#xD;
&#xD;
      Patients and methods: From February 2014 to June 2015, 75 Post-menopausal breast cancer&#xD;
      females' patients were recruited, 53 patients underwent randomization and 45 patients&#xD;
      completed six months, treatment. Aromatase inhibitor (letrozole) was administered as once&#xD;
      daily in accordance to one of the three groups. Control group: fifteen obese females who&#xD;
      received letrozole only; metformin group: fifteen obese females who received the same dose of&#xD;
      letrozole plus metformin (2000 ± 500) mg daily, and lean group: fifteen non- obese breast&#xD;
      cancer females who received letozole for six months, treatment period. Blood samples were&#xD;
      collected at baseline and after six months of aromatase inhibitors treatment for analysis of&#xD;
      serum estradiol, osteocalcin, insulin, leptin, lactate and glucose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in serum level of the study biomarkers after treatment when compared with baseline values</measure>
    <time_frame>six months</time_frame>
    <description>measuring the serum levels of the studied biomarkers</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Metformin</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>fifteen obese females who received letrozole only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fifteen obese females who received the same dose of letrozole plus metformin (2000 ± 500) mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lean group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>fifteen non- obese breast cancer females who received letozole for six months, treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>metformin group</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women, postmenopausal is defined either by:&#xD;
&#xD;
        A. Age ≥ 55 years and one year or more of amenorrhea. B. Age &lt; 55 years and one year or&#xD;
        more of amenorrhea, with an estradiol assay &lt; 20 pg/ml.&#xD;
&#xD;
        • Patients with breast cancer indicated for hormonal treatment with aromatase inhibitors&#xD;
        (overweight 30 &gt; BMI ≥ 25, obese BMI ≥ 30 kg/m2 and non obese BMI between 18 and 25 kg/m2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Diabetic patients.&#xD;
&#xD;
               -  Patients with metabolic syndrome.&#xD;
&#xD;
               -  Patients with last menstrual cycle less than one year ago.&#xD;
&#xD;
               -  Patient with conditions predispose to acidosis (heart failure, renal failure).&#xD;
&#xD;
               -  Ovarian radiation treatment with luteinizing hormone-releasing hormone (LH-RH)&#xD;
                  agonist (goserelin acetate or leuprolide acetate) is not permitted for induction&#xD;
                  of ovarian suppression.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Aya Ahmed El Attar</investigator_full_name>
    <investigator_title>Dr Aya Ahmed El Attar</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

